Out of business since 1999, LXR Biotechnology Inc. had been a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutics to treat diseases associated with the dysregulation of apoptosis (programmed cell death). Previously traded on AMEX - IPO on February 1994, - the moved to NASADQ in August 1999. . Firm ceased public trading completely as of Dec 28, 1999. At that time, the companyâs compounds had included HK-Cardiosolâ¢, CP-Cardiosolâ¢, and Elirexâ¢XR's proprietary compounds, intended as therapies for organ transplant, heart/lung bypass (cardioplegia), heart attack and ischemic s
